Last reviewed · How we verify

NCT06306664

Effect of Two Different Modes of Polarized Polychromatic Non-coherent Light Therapy on Jumper's Knee

Status unknown NA Last updated 12 March 2024
What this trial tests

NA trial testing Bioptron in Jumper's Knee in 60 participants. Status unknown.

Timeline
1 January 2024
Primary endpoint
29 November 2025
1 December 2025

Quick facts

Lead sponsorCairo University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date1 January 2024
Primary completion29 November 2025
Estimated completion1 December 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 15 to 35, any sex, with Jumper's Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purposes of this study are: 1. To examine the combined effects of Yellow CPPNLT and conventional treatment on pain intensity, pain pressure threshold, functional disability, and muscle strength in athletic jumper knee. 2. To examine the combined effects of Green CPPNLT and conventional treatment on pain intensity, pain pressure threshold, functional disability, and muscle strength in athletic jumper knee. 3 3- To compare between the effects of Yellow CPPNLT and Green CPPNLT on pain intensity, pain pressure threshold, functional disability, and muscle strength in athletic jumper knee.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Jumper's Knee

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06306664.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing